<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921180</url>
  </required_header>
  <id_info>
    <org_study_id>950922</org_study_id>
    <nct_id>NCT00921180</nct_id>
  </id_info>
  <brief_title>Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B</brief_title>
  <official_title>Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for the treatment with&#xD;
      HBeAg positive CHB, with the overall HBeAg seroconversion far from satisfactory. Therefore,&#xD;
      efforts on the various combinations with the currently available drugs are needed to improve&#xD;
      the overall response rates. The simultaneous combination therapy with oral nucleoside and&#xD;
      peginterferon alfa-2a from large-scaled randomized trials did not show a superior response&#xD;
      rate over peginterferon alfa-2a monotherapy. Recently, sequential monotherapy with lamivudine&#xD;
      for the first 4 weeks, followed by weekly peginterferon alfa-2a has shown favorable HBeAg&#xD;
      seroconversion rate over peginterferon alfa-2a monotherapy, based on the assumption that&#xD;
      early viral suppression by lamivudine can restore the immune function to facilitate the later&#xD;
      immunomodulatory response by peginterferon alfa-2a. With the recent introduction of&#xD;
      entecavir, the more potent oral nucleoside with few drug resistance, sequential monotherapy&#xD;
      with entecavir can potently suppress HBV DNA with 4 weeks of treatment, which may facilitate&#xD;
      the response of peginterferon alfa-2a to achieve HBeAg seroconversion. Therefore, we aimed to&#xD;
      conduct a placebo controlled randomized control trial to evaluate of adding entecavir early&#xD;
      in the course of therapy can improve the treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B (CHB) is prevalent in the world, with estimated chronic carriers of 350&#xD;
      millions worldwide. Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for&#xD;
      the treatment with HBeAg positive CHB, with the overall HBeAg seroconversion far from&#xD;
      satisfactory. Therefore, efforts on the various combinations with the currently available&#xD;
      drugs are needed to improve the overall response rates. The simultaneous combination therapy&#xD;
      with oral nucleoside and peginterferon alfa-2a from large-scaled randomized trials did not&#xD;
      show a superior response rate over peginterferon alfa-2a monotherapy. Recently, sequential&#xD;
      monotherapy with lamivudine for the first 4 weeks, followed by weekly peginterferon alfa-2a&#xD;
      has shown favorable HBeAg seroconversion rate over peginterferon alfa-2a monotherapy, based&#xD;
      on the assumption that early viral suppression by lamivudine can restore the immune function&#xD;
      to facilitate the later immunomodulatory response by peginterferon alfa-2a. With the recent&#xD;
      introduction of entecavir, the more potent oral nucleoside with few drug resistance,&#xD;
      sequential monotherapy with entecavir can potently suppress HBV DNA with 4 weeks of&#xD;
      treatment, which may facilitate the response of peginterferon alfa-2a to achieve HBeAg&#xD;
      seroconversion. Therefore, we aimed to conduct a placebo controlled randomized control trial&#xD;
      to evaluate of adding entecavir early in the course of therapy can improve the treatment&#xD;
      response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBeAg seroconversion rate 6 months after the cessation of therapy</measure>
    <time_frame>76 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and peginterferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir and peginterferon alfa-2a</intervention_name>
    <description>Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</description>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <other_name>Entecavir (Baraclude) 0.5 mg/day po at week 1-4</other_name>
    <other_name>Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and peginterferon</intervention_name>
    <description>Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</description>
    <arm_group_label>Placebo and peginterferon</arm_group_label>
    <other_name>Placebo 0.5 mg/day po at week 1-4</other_name>
    <other_name>Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B (presence of HBsAg &gt; 6 months) with HBeAg persistence for more&#xD;
             than 3 months&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  HBV DNA &gt; 20,000 IU/mL for more than 2 occasions&#xD;
&#xD;
          -  Serum ALT levels between 2 to 10 folds the upper limit of normal (ULN)&#xD;
&#xD;
          -  A liver biopsy compatible with chronic hepatitis B&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 13 gram per deciliter for men and &lt; 12 gram per deciliter for&#xD;
             women)&#xD;
&#xD;
          -  Neutropenia (neutrophil count &lt;1,500 per cubic milliliter)&#xD;
&#xD;
          -  Thrombocytopenia (platelet &lt;90,000 per cubic milliliter)&#xD;
&#xD;
          -  Co-infection with hepatitis B virus (HBV), hepatitis D virus (HDV) or human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Chronic alcohol abuse (daily consumption &gt; 20 gram per day)&#xD;
&#xD;
          -  Decompensated liver disease (Child-Pugh class B or C)&#xD;
&#xD;
          -  Serum creatinine level more than 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Autoimmune liver disease&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  An organ transplant&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,&#xD;
             psychiatric diseases, neurological diseases, diabetes mellitus Evidence of drug abuse&#xD;
&#xD;
          -  Unwilling to have contraception&#xD;
&#xD;
          -  Known allergic reaction to entecavir or peginterferon alfa-2a&#xD;
&#xD;
          -  Unwilling to sign inform consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hosptial, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Lin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ren-Ai Branch, Taipei City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Sheng Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Shun Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-Hua Liu, MD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>63572</phone_ext>
    <email>jacque_liu@mail2000.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67307</phone_ext>
    <email>kaojh@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hosptial, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Jer Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shih-Jer Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping-Huei Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chieh-Chang Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Lun Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jou-Wei Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Herng Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Shun Yang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sheng-Shun Yang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Hua Liu, MD</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>63572</phone_ext>
      <email>jacque_liu@mail2000.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chen-Hua Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Horng Kao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Jen Liu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Yang Lai, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Jer Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ding-Shinn Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Sheng Hsu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Sheng Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Chi Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tai-Chung Tseng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Chao Liang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheng-Chao Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Lin Lin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chih-Lin Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping-Yeh Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B, chronic</keyword>
  <keyword>Peginterferon alfa-2a</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

